Bleeding related adverse events associated with antiviral treatment in influenza patients: A disproportionality analysis using FDA adverse event reporting system (FAERS)

被引：0
|
作者：
Sarker, Jyotirmoy [1 ]
Carkovic, Emir [2 ]
Lee, Todd A. [3 ]
机构：
[1] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[2] Univ Illinois, Coll Pharm, Chicago, IL USA
[3] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1036
引用
收藏
页码：486 / 487
页数：2
相关论文
共 50 条
  • [31] Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
    Wang, Shiyi
    Wang, Xiaojian
    Ding, Jing
    Zhang, Xudong
    Zhu, Hongmei
    Fan, Yihong
    Sun, Changbo
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [32] Evaluation of Ticagrelor Bleeding Adverse Event Reports Compared to Clopidogrel in the FDA Adverse Events Reporting System (FAERS)
    Fahmy, Ahmed I.
    Mekkawy, Mohamed A.
    Abou-Ali, Adel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 186 - 186
  • [33] Pharmacovigilance Analysis Of FDA Adverse Event Reporting System (FAERS) Events For Inclisiran
    Rajak, Kripa
    Halder, Anupam
    Gautam, Seema Sharma
    Khanal, Resha
    Atrash, Anas
    Goswami, Rohan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [34] Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database
    Nair, Harsha Prakash
    Kulkarni, Apoorva Rachana
    Eswaran, Maheswari
    Subeesh, Viswam
    ARAB JOURNAL OF GASTROENTEROLOGY, 2023, 24 (01) : 1 - 4
  • [35] Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)
    Sharma, Priyanka
    Gupta, Sheeba Varghese
    Bhatt, Priyanka
    Kandukuru, Abhishek
    Cheng, Feng
    Upadhyay, Gunjan
    Sutariya, Vijaykumar
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (12) : 720 - 728
  • [36] Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database
    Wang, Lingling
    Mao, Zhenyu
    Zheng, Pengdou
    Zi, Guisha
    Zhang, Fengqin
    Zhu, Xiaoyan
    Chen, Lixiang
    Liu, Huiguo
    Zhou, Ling
    Wei, Shuang
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [37] Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
    Ding, Lingqing
    Chen, Congqin
    Yang, Yongkuan
    Fang, Jie
    Cao, Longxing
    Liu, Yige
    CARDIOVASCULAR THERAPEUTICS, 2022, 2022
  • [38] Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
    Lin, Shan
    Luo, Dachen
    Gong, Zonglian
    Zhan, Qingyuan
    FRONTIERS IN MEDICINE, 2024, 11
  • [39] Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
    Guo, Haoning
    Wang, Bin
    Yuan, Shuying
    Wu, Silin
    Liu, Jing
    He, Miaoquan
    Wang, Jisheng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [40] A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS)
    Huang, Min
    Li, Peng
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2025, 317 (01)
12345